A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: results from the European Thoracic Oncology Platform (ETOP) Lungscape project
Authors
Kerr, KThunnissen, E
Dafni, U
Finn, SP
Bubendorf, L
Soltermann, A
Verbeken, E
Biernat, W
Warth, A
Marchetti, A
Speel, E
Pokharel, S
Quinn, A
Monkhorst, K
Navarro, A
Madsen, L
Radonic, T
Wilson, J
De Luca, G
Gray, S
Cheney, R
Savic, S
Martorell, M
Muley, T
Baas, P
Meldgaard, P
Blackhall, Fiona H
Dingemans, A
Dziadziuszko, R
Vansteenkiste, J
Weder, W
Polydoropoulou, V
Geiger, T
Kammler, R
Peters, S
Stahel, R
Affiliation
Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, United KingdomIssue Date
2019
Metadata
Show full item recordAbstract
INTRODUCTION: The PD-L1 biomarker is an important factor in selecting patients with non-small cell lung cancer for immunotherapy. While several reports suggest that PD-L1 positivity is linked to a poor prognosis, others suggest that PD-L1 positive status portends a good prognosis. METHODS: PD-L1 positivity prevalence, assessed via immunohistochemistry (IHC) on tissue microarrays (TMAs), and its association with clinicopathological characteristics, molecular profiles and patient outcome- Relapse-free Survival (RFS), Time-to-Relapse (TTR) and Overall Survival (OS)- is explored in the ETOP Lungscape cohort of stage I-III non-small cell lung cancer (NSCLC). Tumors are considered positive if they have ?1/5/25/50% neoplastic cell membrane staining. RESULTS: PD-L1 expression was assessed in 2182 NSCLC cases (2008 evaluable, median follow-up 4.8 years, 54.6% still alive), from 15 ETOP centers. Adenocarcinomas represent 50.9% of the cohort (squamous cell: 42.4%). Former smokers are 53.7% (current: 31.6%, never: 10.5%). PD-L1 positivity prevalence is present in more than one third of the Lungscape cohort (1%/5% cut-offs). It doesn't differ between adenocarcinomas and squamous cell histologies, but is more frequently detected in higher stages, never smokers, larger tumors (1/5/25% cut-offs). With ?1% cut-off it is significantly associated with IHC MET overexpression, expression of PTEN, EGFR and KRAS mutation (only for adenocarcinoma). Results for 5%, 25% and 50% cut-offs were similar, with MET being significantly associated with PD-L1 positivity both for AC (p?<?0.001, 5%/25%/50% cut-offs) and SCC (p?<?0.001, 5% & 50% cut-offs and p?=?0.0017 for 25%). When adjusting for clinicopathological characteristics, a significant prognostic effect was identified in adenocarcinomas (adjusted p-values: 0.024/0.064/0.063 for RFS/TTR/OS 1% cut-off, analogous for 5%/25%, but not for 50%). Similar results obtained for the model including all histologies, but no effect was found for the squamous cell carcinomas. CONCLUSION: PD-L1 positivity, when adjusted for clinicopathological characteristics, is associated with a better prognosis for non-metastatic adenocarcinoma patients.Citation
Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, et al. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: results from the European Thoracic Oncology Platform (ETOP) Lungscape project. Lung Cancer. 2019; 131:95-103.Journal
Lung CancerDOI
10.1016/j.lungcan.2019.03.012PubMed ID
31027705Additional Links
https://dx.doi.org/10.1016/j.lungcan.2019.03.012Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.lungcan.2019.03.012
Scopus Count
Collections
Related articles
- Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial.
- Authors: Peters S, Letovanec I, Mauer M, Dafni U, Ejedepang D, Biernat W, Bubendorf L, Warth A, Pokharel S, Reinmuth N, Majem Tarruella M, Casas-Martin J, Tsourti Z, Marti N, Kammler R, Danson S, O'Brien M, Stahel RA
- Issue date: 2023 Jan
- Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
- Authors: Cruz-Rico G, Avilés-Salas A, Popa-Navarro X, Lara-Mejía L, Catalán R, Sánchez-Reyes R, López-Sánchez D, Cabrera-Miranda L, Aquiles Maldonado-Martínez H, Samtani-Bassarmal S, Arrieta O
- Issue date: 2021
- Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer.
- Authors: Montero MA, Aricak O, Kis L, Yoshikawa A, De Petris L, Grundberg O, Pham HHN, Roden AC, Fukuoka J, Attanoos R, Guijarro R, Alarcón F, Lindström K, Ortiz-Villalón C
- Issue date: 2021 Apr
- The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
- Authors: Takada K, Okamoto T, Toyokawa G, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y
- Issue date: 2017 Feb
- Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.
- Authors: Bubendorf L, Dafni U, Schöbel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E, Verbeken EK, Warth A, Sansano I, Cheney R, Speel EJM, Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourti Z, Geiger TR, Kammler R, Schulze K, Das-Gupta A, Shames D, Peters S, Stahel RA, Lungscape Consortium
- Issue date: 2017 Sep